Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)
ICH幸存者的抗凝治疗以预防和恢复(ASPIRE)
基本信息
- 批准号:10170976
- 负责人:
- 金额:$ 50.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcuteAcute Brain InjuriesAddressAdmission activityAffectAnticoagulant therapyAnticoagulantsAnticoagulationAspirinAtrial FibrillationBlindedBloodBrain InjuriesBrain hemorrhageC-reactive proteinCOVID-19COVID-19 pandemicCerebral InfarctionCerebral hemisphere hemorrhageCessation of lifeClinicalClinical TrialsCollaborationsCommunitiesComplicationComputer InterfaceCritical CareCritical IllnessDataData SetDecontaminationDetectionDevicesDiseaseDouble-Blind MethodElectromagneticsEndotheliumEnrollmentFaceFerritinFibrin fragment DFoundationsFrightFunctional disorderFutureGeneral HospitalsGuidelinesHeadHemorrhageImageInfectionInflammatoryInfrastructureInpatientsIntensive Care UnitsIntervention StudiesIntracranial HemorrhagesIschemic StrokeKnowledgeLeadLinkLiquid substanceMagnetic Resonance ImagingMassachusettsMeasuresMedicalMissionMulticenter StudiesNational Institute of Neurological Disorders and StrokeNatureNeuraxisNeurologicNeurological ModelsOralOutcomePatient-Focused OutcomesPatientsPhasePhenotypePhysiologicalPreventionPrevention therapyPrevention trialPreventive InterventionProtocols documentationPublic HealthRandomizedRandomized Clinical TrialsRecording of previous eventsRecoveryRecurrenceReportingResearch DesignRiskRisk FactorsSafetySerologicalSeveritiesSiteStrokeStroke preventionSurvivorsSymptomsTablet ComputerTestingThrombophiliaThrombosisUnited States National Institutes of HealthVentilatorWorkWritingantimicrobialbasebody systembrain healthclinical careclinical practiceclinical riskcohortcomorbiditycoronavirus diseasecryogenicsdisabilityepidemiological modelfallsfunctional outcomesfunctional statusheart rhythmhigh riskimprovedimproved outcomeinstrumentmortalityneuroimagingnovelpatient orientedpatient populationportabilitypredictive modelingpreventprimary outcomepublic health relevancerecruitsecondary endpointstroke risk
项目摘要
Atrial fibrillation, the most common heart-rhythm disorder, increases the risk of ischemic stroke by 3- to 5-fold. Anticoagulant therapy has been proven to prevent 60-80% of ischemic strokes that would otherwise occur from atrial fibrillation. Patients with a history of intracerebral hemorrhage have been excluded from clinical trials of anticoagulation in patients with atrial fibrillation. Whether to use anticoagulation in these patients represents a major knowledge gap and clinical dilemma. Many clinicians fear that the proven benefit of anticoagulation in preventing ischemic stroke will be offset by an increase in hemorrhagic stroke. Preliminary data from multicenter studies indicate that, in patients with atrial fibrillation and recent intracerebral hemorrhage, anticoagulation is associated with a decreased risk of ischemic stroke and overall mortality with no offsetting increase in the burden of recurrent hemorrhagic stroke. These pilot data also suggest that anticoagulation is associated with better long-term functional outcomes. Although these data are compelling, they are observational findings and subject to confounding and bias. In clinical practice, about one-third of patients with intracerebral hemorrhage and atrial fibrillation receive anticoagulation and the remainder receive antiplatelet therapy such as aspirin. Current clinical guidelines call for randomized, blinded clinical trials to provide high-quality evidence to determine the best treatment. The argument for a clinical trial is made more compelling by the advent of apixaban, a relatively new oral anticoagulant drug, which was found to have similar bleeding risks as aspirin in a recent head-to-head trial. This application is for a multicenter, double-blinded, randomized clinical trial of apixaban versus aspirin in patients with atrial fibrillation and a recent intracerebral hemorrhage. Seven hundred patients will be recruited and followed for 1 to 3 years at 125 sites in NINDS StrokeNet. The aim of the study will be to test the hypothesis that apixaban improves outcomes compared to aspirin. The primary outcome will be any stroke (ischemic or hemorrhagic) or death. This composite outcome addresses both efficacy and safety, and represents a clinically meaningful endpoint often used in stroke prevention trials. The secondary endpoint will be functional status, as measured by the modified Rankin Scale score. This secondary endpoint will be used to test the hypothesis that apixaban not only reduces stroke recurrence but also the severity of any strokes that do occur. If confirmed, this novel finding would provide an important patient-centered context for the primary trial results. This proposal offers an opportunity to improve the outcomes of patients with intracerebral hemorrhage by focusing on their brain health both in the acute setting and over the long term. The impact of this study is that its successful completion, regardless of the direction of its results, would immediately guide clinical care and set the stage for future trials of antithrombotic therapy in patients with atrial fibrillation and other types of bleeding.
房颤是最常见的心律失常,可使缺血性中风的风险增加3至5倍。抗凝治疗已被证明可以预防60-80%的缺血性中风,否则会发生房颤。有脑出血病史的患者已从房颤患者抗凝治疗的临床试验中排除。是否在这些患者中使用抗凝治疗是一个主要的知识缺口和临床困境。许多临床医生担心,抗凝治疗在预防缺血性卒中方面已证实的益处将被出血性卒中的增加所抵消。来自多中心研究的初步数据表明,在房颤和近期脑出血患者中,抗凝治疗与缺血性卒中风险降低和总体死亡率降低相关,而复发性出血性卒中的负担没有抵消性增加。这些初步数据还表明,抗凝治疗与更好的长期功能结局相关。虽然这些数据是令人信服的,但它们是观察性发现,并受到混淆和偏见的影响。在临床实践中,约三分之一的脑出血和房颤患者接受抗凝治疗,其余患者接受抗血小板治疗,如阿司匹林。目前的临床指南要求进行随机、盲法临床试验,以提供高质量的证据来确定最佳治疗。阿哌沙班是一种相对较新的口服抗凝药物,在最近的一项头对头试验中发现其出血风险与阿司匹林相似。本申请是一项比较阿哌沙班与阿司匹林治疗房颤和近期脑出血患者的多中心、双盲、随机临床试验。将在NINDS StrokeNet的125个研究中心招募700名患者并随访1至3年。该研究的目的是检验与阿司匹林相比,阿哌沙班改善结局的假设。主要结局为任何卒中(缺血性或出血性)或死亡。这一复合结局同时解决了疗效和安全性问题,代表了卒中预防试验中经常使用的具有临床意义的终点。次要终点为功能状态,通过改良兰金量表评分进行测量。该次要终点将用于检验以下假设:阿哌沙班不仅可降低卒中复发率,还可降低任何卒中的严重程度。如果得到证实,这一新发现将为主要试验结果提供一个重要的以患者为中心的背景。这项建议提供了一个机会,以改善脑出血患者的结果,重点是他们的大脑健康,无论是在急性环境和长期。这项研究的影响是,无论其结果的方向如何,它的成功完成将立即指导临床护理,并为房颤和其他类型出血患者的抗血栓治疗的未来试验奠定基础。
项目成果
期刊论文数量(42)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of Intensive Blood Pressure Control on Incident Stroke Risk in Patients With Mild Cognitive Impairment.
- DOI:10.1161/strokeaha.122.038818
- 发表时间:2022-07
- 期刊:
- 影响因子:8.3
- 作者:de Havenon, Adam;Sharma, Richa;Falcone, Guido J.;Prabhakaran, Shyam;Sheth, Kevin N.
- 通讯作者:Sheth, Kevin N.
Disability Status and Secondary Prevention Among Survivors of Stroke: A Cross-Sectional Analysis of the 2011 to 2018 National Health and Nutrition Examination Survey.
- DOI:10.1161/jaha.123.030869
- 发表时间:2023-12-05
- 期刊:
- 影响因子:5.4
- 作者:
- 通讯作者:
Anticoagulation after intracerebral hemorrhage: a perfect clinical scenario for genetics-based precision medicine.
脑出血后抗凝:基于遗传学的精准医学的完美临床方案。
- DOI:10.2217/pgs-2019-0181
- 发表时间:2020
- 期刊:
- 影响因子:2.1
- 作者:Brown,StacyC;Sheth,KevinN;Falcone,GuidoJ
- 通讯作者:Falcone,GuidoJ
Analysis of Clinical Traits Associated With Cardiovascular Health, Genomic Profiles, and Neuroimaging Markers of Brain Health in Adults Without Stroke or Dementia.
- DOI:10.1001/jamanetworkopen.2022.15328
- 发表时间:2022-05-02
- 期刊:
- 影响因子:13.8
- 作者:Acosta, Julian N.;Both, Cameron P.;Rivier, Cyprien;Szejko, Natalia;Leasure, Audrey C.;Gill, Thomas M.;Payabvash, Seyedmehdi;Sheth, Kevin N.;Falcone, Guido J.
- 通讯作者:Falcone, Guido J.
Effect of Primary Prophylactic Antiseizure Medication for Seizure Prevention Following Intracerebral Hemorrhage in the ERICH Study.
- DOI:10.1016/j.jstrokecerebrovasdis.2021.106143
- 发表时间:2022-01
- 期刊:
- 影响因子:2.5
- 作者:Savalia, Krupa;Sekar, Padmini;Moomaw, Charles J.;Koch, Sebastian;Sheth, Kevin N.;Woo, Daniel;Mayson, Douglas
- 通讯作者:Mayson, Douglas
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hooman Kamel其他文献
Hooman Kamel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hooman Kamel', 18)}}的其他基金
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)
ICH幸存者的抗凝治疗以预防和恢复(ASPIRE)
- 批准号:
10159987 - 财政年份:2019
- 资助金额:
$ 50.28万 - 项目类别:
Left Atrial abNormality, ThromboEmbolism, and Race: Novel risk factors for stroke (LANTERN)
左心房异常、血栓栓塞和种族:中风的新危险因素 (LANTERN)
- 批准号:
9156264 - 财政年份:2016
- 资助金额:
$ 50.28万 - 项目类别:
Left Atrial abNormality, ThromboEmbolism, and Race: Novel risk factors for stroke (LANTERN)
左心房异常、血栓栓塞和种族:中风的新危险因素 (LANTERN)
- 批准号:
9270634 - 财政年份:2016
- 资助金额:
$ 50.28万 - 项目类别:
Atrial Fibrillation Precursors May Be Novel Stroke Risk Factors
心房颤动前兆可能是新的中风危险因素
- 批准号:
9120951 - 财政年份:2013
- 资助金额:
$ 50.28万 - 项目类别:
Atrial Fibrillation Precursors May Be Novel Stroke Risk Factors
心房颤动前兆可能是新的中风危险因素
- 批准号:
8719849 - 财政年份:2013
- 资助金额:
$ 50.28万 - 项目类别:
Atrial Fibrillation Precursors May Be Novel Stroke Risk Factors
心房颤动前兆可能是新的中风危险因素
- 批准号:
9334941 - 财政年份:2013
- 资助金额:
$ 50.28万 - 项目类别:
Atrial Fibrillation Precursors May Be Novel Stroke Risk Factors
心房颤动前兆可能是新的中风危险因素
- 批准号:
8634871 - 财政年份:2013
- 资助金额:
$ 50.28万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 50.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 50.28万 - 项目类别:
Operating Grants